Gavreto

A drug used to treat adults with non-small cell lung cancer that has a RET fusion gene and has spread to other parts of the body and adults and children aged 12 years and older with thyroid cancer that has a RET fusion gene, has spread, and needs treatment with systemic therapy. This includes patients whose thyroid cancer did not respond to radioactive iodine. It is also being studied in the treatment of other types of cancer. Gavreto blocks certain proteins made by the RET fusion gene, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called pralsetinib.